A study of patients with ovarian cancer highlights the need to identify the mechanisms of resistance to PARP inhibitors to find effective therapies for this tumour
Retreatment with platinum-based chemotherapy as a therapy for relapsed ovarian cancer after progression to PARP inhibitors shows different results for patients with BRCA-mutated and BRCA wild-type tumours.
